FBRX · Forte Biosciences, Inc.

$76.99 +0.02 (+0.03%) At close · Aug 26

Market Cap

$1.63B

21.23M

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date	Headline
2026-07-27	argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
2026-07-09	FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period
2026-05-11	Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
2026-05-11	Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update
2026-04-09	Forte Biosciences Announces Pricing of $150 Million Public Offering
2026-04-08	Forte Biosciences Announces Proposed Public Offering
2026-03-31	Forte Biosciences, Inc. Announces 2025 Results and Provides Update
2026-03-17	Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
2026-03-04	Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules
2026-02-09	Forte Biosciences, Inc. to Present at Upcoming Investor Meetings
2025-12-22	Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

Past events

Date	Event	Type
2026-07-09	Forte FB102 Data Call	Event
2025-09-15	Tampere Celiac Disease Symposium 2025 FB102 Phase 1b Oral Presentation	Presentation
2025-06-23	Forte Biosciences Webcast to Discuss Positive Data in FB102 Celiac Disease Phase 1B Study	Webcast
2024-06-14	Notice to Stockholders	Shareholder meeting

Source: https://www.fortebiorx.com/investor-relations/news/default.aspx

Key facts CIK 1419041 CUSIP 34962G208 13F (30d) 88 filings 85 filers Visit website Investor relations